Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells

  1. Wenxian Fu
  2. Julia Farache
  3. Susan M Clardy
  4. Kimie Hattori
  5. Palwinder Mander
  6. Kevin Lee
  7. Inmaculada Rioja
  8. Ralph Weissleder
  9. Rab K Prinjha
  10. Christophe Benoist
  11. Diane Mathis  Is a corresponding author
  1. University of California, San Diego, United States
  2. Harvard Medical School, United States
  3. Massachusetts General Hospital, Harvard Medical School, United States
  4. GlaxoSmithKline, United Kingdom
  5. Pfizer, United States

Abstract

Epigenetic modifiers are an emerging class of anti-tumor drugs, potent in multiple cancer contexts. Their effect on spontaneously developing autoimmune diseases has been little explored. We report that a short treatment with I-BET151, a small-molecule inhibitor of a family of bromodomain-containing transcriptional regulators, irreversibly suppressed development of type-1 diabetes in NOD mice. The inhibitor could prevent or clear insulitis, but had minimal influence on the transcriptomes of infiltrating and circulating T cells. Rather, it induced pancreatic macrophages to adopt an anti-inflammatory phenotype, impacting the NF-κB pathway in particular. I-BET151 also elicited regeneration of islet β-cells, inducing proliferation and expression of genes encoding transcription factors key to β-cell differentiation/function. The effect on β cells did not require T cell infiltration of the islets. Thus, treatment with I-BET151 achieves a 'combination therapy,' currently advocated by many diabetes investigators, operating by a novel mechanism that coincidentally dampens islet inflammation and enhances β-cell regeneration.

Article and author information

Author details

  1. Wenxian Fu

    University of California, San Diego, La Jolla, United States
    Competing interests
    No competing interests declared.
  2. Julia Farache

    Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  3. Susan M Clardy

    Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  4. Kimie Hattori

    Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Palwinder Mander

    GlaxoSmithKline, Stevenage, United Kingdom
    Competing interests
    Palwinder Mander, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.
  6. Kevin Lee

    Pfizer, Cambridge, United States
    Competing interests
    Kevin Lee, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.
  7. Inmaculada Rioja

    GlaxoSmithKline, Stevenage, United Kingdom
    Competing interests
    Inmaculada Rioja, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors..
  8. Ralph Weissleder

    Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. Rab K Prinjha

    GlaxoSmithKline, Stevenage, United Kingdom
    Competing interests
    Rab K Prinjha, GlaxoSmithKline has an ongoing interest in the therapeutic applications of BET-protein inhibitors.
  10. Christophe Benoist

    Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  11. Diane Mathis

    Harvard Medical School, Boston, United States
    For correspondence
    diane_mathis@hms.harvard.edu
    Competing interests
    Diane Mathis, Reviewing editor, eLife.

Ethics

Animal experimentation: NOD/Lt mice were bred under specific-pathogen-free conditions in our animal facility at the New Research Building of Harvard Medical School, cared for in accordance with the ethical guidelines of the Institutional Animal Care and Use Committee (#02954). Relevant studies were also conducted in accordance with GSK's Policy on the Care, Welfare and Treatment of Laboratory Animals. NOD.Cg-Rag1<tm1mom> mice were maintained in our lab's colony at Jackson Laboratory.

Copyright

© 2014, Fu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,345
    views
  • 693
    downloads
  • 69
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Wenxian Fu
  2. Julia Farache
  3. Susan M Clardy
  4. Kimie Hattori
  5. Palwinder Mander
  6. Kevin Lee
  7. Inmaculada Rioja
  8. Ralph Weissleder
  9. Rab K Prinjha
  10. Christophe Benoist
  11. Diane Mathis
(2014)
Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells
eLife 3:e04631.
https://doi.org/10.7554/eLife.04631

Share this article

https://doi.org/10.7554/eLife.04631

Further reading

    1. Immunology and Inflammation
    Jian Liu, YuYing Jiang ... ZhiQiang Yin
    Research Article

    Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell-related abnormalities. Pyroptosis is a type of regulated cell death associated with innate immunity, but its role in psoriasis is unclear. In this study, we found that gasdermin D (GSDMD) is higher in human psoriatic skin than that in normal skin, and in imiquimod-induced psoriasis-like mouse skin, the expression of Gsdmd was most significantly altered in neutrophils and Il1b was also mainly expressed in neutrophils. Immunohistochemical staining of serial sections of skin lesions from psoriasis patients and healthy control also showed that GSDMD expression is higher in psoriasis lesion, especially in neutrophils. Gsdmd deficiency mitigates psoriasis-like inflammation in mice. GSDMD in neutrophils contributes to psoriasis-like inflammation, while Gsdmd depletion in neutrophils attenuates the development of skin inflammation in psoriasis and reduces the release of the inflammatory cytokines. We found that neutrophil pyroptosis is involved in and contributes to psoriasis inflammation, which provides new insights into the treatment of psoriasis by targeting neutrophil pyroptosis.

    1. Immunology and Inflammation
    Matteo Napoli, Roland Immler ... Monika Pruenster
    Research Article

    S100A8/A9 is an endogenous alarmin secreted by myeloid cells during many acute and chronic inflammatory disorders. Despite increasing evidence of the proinflammatory effects of extracellular S100A8/A9, little is known about its intracellular function. Here, we show that cytosolic S100A8/A9 is indispensable for neutrophil post-arrest modifications during outside-in signaling under flow conditions in vitro and neutrophil recruitment in vivo, independent of its extracellular functions. Mechanistically, genetic deletion of S100A9 in mice caused dysregulated Ca2+ signatures in activated neutrophils resulting in reduced Ca2+ availability at the formed LFA-1/F-actin clusters with defective β2 integrin outside-in signaling during post-arrest modifications. Consequently, we observed impaired cytoskeletal rearrangement, cell polarization, and spreading, as well as cell protrusion formation in S100a9-/- compared to wildtype (WT) neutrophils, making S100a9-/- cells more susceptible to detach under flow, thereby preventing efficient neutrophil recruitment and extravasation into inflamed tissue.